Hesperos Seeks $21 Million For Animal-Free Toxicology Testing System

Jul. 15, 2022 1:48 PM ETHesperos, Inc. (HESP)FPX, FPXI, IPO, GTIP, CSD, SPAK, IPOS, FPXE, DSPC


  • Hesperos has filed to raise around $21 million in an IPO.
  • The firm is developing an animal-free toxicology testing platform.
  • HESP is still in development for its platform and has produced contracting and uneven financial results.
  • I'll provide a final opinion when we learn more IPO details.
  • Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More »


artisteer/iStock via Getty Images

A Quick Take On Hesperos

Hesperos (HESP) has filed to raise $21.25 million in an IPO of its common stock, according to an S-1 registration statement.

The firm provides chemical and therapeutic testing capabilities through its chip platform.

When we learn more pricing and valuation details from management, I'll provide a final opinion.

Hesperos Overview

Orlando, Florida-based Hesperos was founded to develop what it calls a "Human-on-a-Chip" system for pre-clinical toxicology testing.

Management is headed by Chief Executive Officer, James F. Kronauge, Jr., Ph.D., who has been with the firm since April 1, 2022 and was Vice President of Process Development at Cystosite Biopharma and has held a variety of senior roles at various other biotechnology companies.

The system promises to reduce the need for animal testing and can be configured for specific customer requirements.

The company has received a number of SBIR grants from the National Institute of Health.

Hesperos has booked fair market value investment of $1 million as of March 31, 2022 from investors including CEO Kronauge.

Hesperos - Customer Acquisition

To-date, the company has funded its operations primarily from NIH grant funding, with some revenue from pharma and cosmetic industry clients.

The firm has received $17.5 million in NIH as of March 31, 2021 with an additional $7.4 million in potential funding through 2024.

General & Administrative expenses as a percentage of total revenue have risen as revenues have decreased, as the figures below indicate:

General & Administrative

Expenses vs. Revenue



Three Mos. Ended March 31, 2022






(Source - SEC)

The General & Administrative efficiency multiple, defined as how many dollars of additional new revenue are generated by each dollar of General & Administrative spend, fell to negative (0.1x) in the most recent reporting period, as shown in the table below:

General & Administrative

Efficiency Rate



Three Mos. Ended March 31, 2022




(Source - SEC)

Hesperos' Market & Competition

According to a 2021 market research report by Grand View Research, the global market for in vitro toxicology testing was an estimated $22.7 billion in 2020 and is forecast to reach $51.2 billion by 2028.

This represents a forecast CAGR of 10.7% from 2021 to 2028.

The main drivers for this expected growth are the increasing costs associated with animal testing, lack of available animal models and growing ethical concerns with animal testing.

Also, the chart below shows the breakdown of use cases for toxicology testing worldwide:

Global In-Vitro Toxicology Testing Market

Global In-Vitro Toxicology Testing Market (Grand View Research)

Major competitive or other industry participants include:

  • TissUs

  • Emulate

  • HuREL

  • Mimetas

  • Hepregan

  • InSphero

  • CN Bio Innovations

  • Nortis

  • Organovo

  • TARA Biosystems

  • Scikon

  • 4Design Bioscience

  • RegeneMed

Hesperos' Financial Performance

The company's recent financial results can be summarized as follows:

  • Contracting topline revenue

  • Reduced gross profit and gross margin

  • Growing operating losses

  • Cash used in operations

Below are relevant financial results derived from the firm's registration statement:

Total Revenue


Total Revenue

% Variance vs. Prior

Three Mos. Ended March 31, 2022

$ 1,103,181



$ 5,197,370



$ 5,242,376

Gross Profit (Loss)


Gross Profit (Loss)

% Variance vs. Prior

Three Mos. Ended March 31, 2022

$ 263,227



$ 1,473,054



$ 1,494,016

Gross Margin


Gross Margin

Three Mos. Ended March 31, 2022






Operating Profit (Loss)


Operating Profit (Loss)

Operating Margin

Three Mos. Ended March 31, 2022

$ (325,221)



$ (375,874)



$ (82,702)


Net Income (Loss)


Net Income (Loss)

Net Margin

Three Mos. Ended March 31, 2022

$ (347,932)



$ (483,544)



$ 64,713


Cash Flow From Operations


Cash Flow From Operations

Three Mos. Ended March 31, 2022

$ (91,921)


$ 186,988


$ 182,932

(Glossary Of Terms)

(Source - SEC)

As of March 31, 2022, Hesperos had $282,745 in cash and $4.5 million in total liabilities.

Free cash flow during the twelve months ended March 31, 2022, was $57,391.

Hesperos' IPO Details

Hesperos intends to raise $21.25 million in gross proceeds from an IPO of its common stock, although the final figure may differ.

No existing shareholders have indicated an interest to purchase shares at the IPO price.

Management says it will use the net proceeds from the IPO as follows:

to enhance the fabrication of our Human-on-a-Chip system;

to automate our system's measurement processes in order to increase throughput and attain consistent quality;

to invest in research and lab staff;

to hire sales and marketing staff to target pharmaceutical companies and a broader set of commercial companies; and

the remaining amounts to fund working capital and general corporate purposes.

We believe that our existing cash and cash equivalents, together with the net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 36 months.

(Source - SEC)

Management's presentation of the company roadshow is not available.

Regarding outstanding legal proceedings, management says there are no current legal claims that would have a material adverse effect on its financial condition or operations.

The sole listed bookrunner of the IPO is ThinkEquity.

Commentary About Hesperos' IPO

HESP is seeking public capital market investment to fund further development of its platform and for initial commercialization efforts.

The firm's financials have reported lowered topline revenue, less gross profit and gross margin, increasing operating losses and a swing to cash used in operations.

Free cash flow for the twelve months ended March 31, 2022, was $57,391.

General & Administrative expenses as a percentage of total revenue have risen considerably as revenue has decreased; its General & Administrative efficiency multiple was a negative (0.1x) in the most recent reporting period.

The firm currently plans to pay no dividends and will retain future available funds for its continued development and growth plans.

The market opportunity for providing toxicology testing is large and expected to grow at a substantial rate of growth in the coming years, so the company enjoys favorable market growth dynamics.

ThinkEquity is the lead underwriter and IPOs led by the firm over the last 12-month period have generated an average return of negative (67.7%) since their IPO. This is a bottom-tier performance for all major underwriters during the period.

The primary risk to the company's outlook is the potential for slow acceptance of its synthetic approach to toxicology testing

The company has a history of surviving on NIH grants, which can make it difficult to transition into a commercial business while weaning itself off of grant revenue.

When we learn more IPO details from management, I'll provide an update.

Expected IPO Pricing Date: To be announced.

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis.

Get started with a free trial!

This article was written by

Donovan Jones profile picture
Author of IPO Edge
Get IPO Edge with actionable research on next-generation high growth stocks

I'm the founder of IPO Edge on Seeking Alpha, a research service for investors interested in IPOs on US markets. Subscribers receive access to my proprietary research, valuation, data, commentary, opinions, and chat on U.S. IPOs. Join now to get an insider's 'edge' on new issues coming to market, both before and after the IPO. Start with a 14-day Free Trial.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This report is intended for educational purposes only and is not financial, legal or investment advice. The information referenced or contained herein may change, be in error, become outdated and irrelevant, or removed at any time without notice. You should perform your own research for your particular financial situation before making any decisions. IPO investing can involve significant volatility and risk of loss.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.